The cardioprotective effects of GLP-1 are well described [133] and GLP-1 agonists such as exenatide were shown to improve NASH, vessel inflammation, and plaque size [134]. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatohepatitis.